On May 22, 2024 Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, reported that two podium presentations and multiple posters featuring data for the company’s NeXT Personal whole genome-based, tumor-informed assay for ultra-sensitive ctDNA detection will be presented at the 2024 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting, which convenes from May 31-June 4, 2024, in Chicago, Illinois (Press release, Personalis, MAY 22, 2024, View Source [SID1234643557]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"As the body of studies continues to grow that demonstrates the role our ultra-sensitive MRD test, NeXT Personal, can play in identifying recurrent cancer early, we were honored to learn that two Personalis studies were selected as podium presentations at ASCO (Free ASCO Whitepaper) 2024’s Clinical Science Symposium", said Dr. Richard Chen, Chief Medical Officer and Executive Vice President, R&D at Personalis.
The two studies that were selected to appear as podium presentations are:
Clinical Science Symposium: Emerging Role of ctDNA in Breast Cancer
Presenter: Isaac Garcia-Murillas, PhD
Overview: Ultra-sensitive ctDNA mutation tracking to identify molecular residual disease and predict relapse in patients with early breast cancer.
Abstract Number: 1010
Clinical Science Symposium: Hitting the Mark – The Ongoing Search for Immunotherapy Biomarkers
Presenter: Rodrigo A Toledo, PhD, MBA
Overview: Prognostic and predictive value of ultrasensitive ctDNA monitoring in a metastatic pan-cancer cohort treated with immune checkpoint inhibitors in the context of phase 1 clinical trials.
Abstract Number: 2510
Details of the Personalis abstracts are outlined below, and further details about the poster presentations can be found here.
Abstract Title: Emerging Role of ctDNA in Breast Cancer
Presenter: Andrew B. Nixon PhD, MBA
Overview: Ultra-sensitive ctDNA dynamics to capture therapy response in pembrolizumab-treated gastroesophageal cancer.
Abstract Number: 4025
Abstract Title: Breast Cancer—Local/Regional/Adjuvant
Presenter: Adrienne Gropper Waks, MD
Overview: Prevalence and dynamics of circulating tumor DNA (ctDNA) among patients (pts) with HER2+ breast cancer (BC) receiving neoadjuvant paclitaxel/trastuzumab/pertuzumab (THP) in the DAPHNe trial.
Abstract Number: 588
Publication Title: Gastrointestinal Cancer—Colorectal and Anal
First Author: Joao Paulo Solar Vasconcelos, MD
Overview: Circulating tumor DNA (ctDNA) kinetics in colorectal cancer (CRC) treated with curative intent in the VICTORI study with an ultrasensitive MRD assay.
Abstract Number: e15625